ES2627944T3 - Composiciones y métodos de tratamiento de hipertensión pulmonar - Google Patents

Composiciones y métodos de tratamiento de hipertensión pulmonar Download PDF

Info

Publication number
ES2627944T3
ES2627944T3 ES11833507.4T ES11833507T ES2627944T3 ES 2627944 T3 ES2627944 T3 ES 2627944T3 ES 11833507 T ES11833507 T ES 11833507T ES 2627944 T3 ES2627944 T3 ES 2627944T3
Authority
ES
Spain
Prior art keywords
ambrisentan
tadalafil
salt
composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11833507.4T
Other languages
English (en)
Spanish (es)
Inventor
Luiz Belardinelli
Hunter Campbell Gillies
Faquan Liang
John Shryock
Suya Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2627944(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2627944T3 publication Critical patent/ES2627944T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES11833507.4T 2010-10-15 2011-10-14 Composiciones y métodos de tratamiento de hipertensión pulmonar Active ES2627944T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39352910P 2010-10-15 2010-10-15
US393529P 2010-10-15
US201161490454P 2011-05-26 2011-05-26
US201161490454P 2011-05-26
US201161497475P 2011-06-15 2011-06-15
US201161497475P 2011-06-15
PCT/US2011/056404 WO2012051559A2 (en) 2010-10-15 2011-10-14 Compositions and methods of treating pulmonary hypertension

Publications (1)

Publication Number Publication Date
ES2627944T3 true ES2627944T3 (es) 2017-08-01

Family

ID=45939010

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11833507.4T Active ES2627944T3 (es) 2010-10-15 2011-10-14 Composiciones y métodos de tratamiento de hipertensión pulmonar

Country Status (25)

Country Link
US (3) US20120269898A1 (de)
EP (2) EP3106163A1 (de)
JP (2) JP5806320B2 (de)
KR (2) KR20150002876A (de)
CN (1) CN103458690B (de)
AR (1) AR083422A1 (de)
AU (2) AU2011315891B2 (de)
BR (1) BR112013008983A2 (de)
CA (1) CA2814518C (de)
CY (1) CY1119007T1 (de)
DK (1) DK2637664T3 (de)
EA (2) EA026074B1 (de)
ES (1) ES2627944T3 (de)
HR (1) HRP20170848T1 (de)
HU (1) HUE033346T2 (de)
LT (1) LT2637664T (de)
MX (1) MX346730B (de)
NZ (2) NZ610012A (de)
PL (1) PL2637664T3 (de)
PT (1) PT2637664T (de)
RS (1) RS56135B1 (de)
SI (1) SI2637664T1 (de)
TW (1) TWI542580B (de)
WO (1) WO2012051559A2 (de)
ZA (1) ZA201302746B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101777B1 (de) 2006-12-12 2015-05-20 Gilead Sciences, Inc. Zusammensetzung zur behandlung einer pulmonalen hypertonie
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
WO2015069839A1 (en) * 2013-11-06 2015-05-14 Gilead Sciences, Inc. Combination therapy for treating pulmonary hypertension
CN105581990A (zh) * 2014-08-27 2016-05-18 人福医药集团股份公司 安立生坦片剂及其制备方法
CA2982436C (en) 2015-03-13 2023-09-12 Indiana University Research And Technology Corporation Targeting cgmp-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
RS62011B1 (sr) * 2016-07-15 2021-07-30 Acceleron Pharma Inc Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
WO2019010445A1 (en) * 2017-07-07 2019-01-10 The Regents Of The University Of Colorado, A Body Corporate COMPOSITIONS AND METHOD FOR THE TREATMENT OF PULMONARY HYPERTENSION
JP2021509114A (ja) 2017-12-26 2021-03-18 エフティーエフ ファーマ プライベート リミテッド Ｐｄｅ ｖ阻害剤のための液体経口処方物
CN109406688A (zh) * 2018-09-28 2019-03-01 中国食品药品检定研究院 用于检测产品中违禁药品的标准样品
MX2022006403A (es) * 2019-11-29 2022-08-25 Actelion Pharmaceuticals Ltd Metodos de tratamiento de hipertension de la arteria pulmonar.
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN112826944B (zh) * 2021-01-29 2023-08-15 台州职业技术学院 一种安立生坦包合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
EP1776108A1 (de) 2004-06-23 2007-04-25 Myogen, Inc. Enoximon-formulierungen und ihre verwendung bei der behandlung von pde-iii-vermittelten erkrankungen
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN101072564A (zh) * 2004-08-26 2007-11-14 恩希赛弗制药公司 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
ATE513831T1 (de) 2006-04-21 2011-07-15 Pfizer Prod Inc Pyridinä3,4-büpyrazinone
EP2101777B1 (de) 2006-12-12 2015-05-20 Gilead Sciences, Inc. Zusammensetzung zur behandlung einer pulmonalen hypertonie
EP2091539A1 (de) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan in kombination mit einem reninhemmer gegen bluthochdruck
EP2183223A2 (de) 2007-07-31 2010-05-12 Gilead Colorado, Inc. Metabolite und derivate von ambrisentan
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
MX346730B (es) 2010-10-15 2017-03-30 Gilead Sciences Inc Composiciones y metodos para el tratamiento de la hipertension pulmonar.

Also Published As

Publication number Publication date
NZ707213A (en) 2016-12-23
US20120269898A1 (en) 2012-10-25
MX2013004190A (es) 2013-07-29
AU2016204638B2 (en) 2018-06-07
WO2012051559A3 (en) 2013-10-17
EA026074B1 (ru) 2017-02-28
EP2637664B1 (de) 2017-03-29
TWI542580B (zh) 2016-07-21
HRP20170848T1 (hr) 2017-08-25
EP2637664A2 (de) 2013-09-18
PT2637664T (pt) 2017-06-22
SI2637664T1 (sl) 2017-07-31
AR083422A1 (es) 2013-02-21
CY1119007T1 (el) 2018-01-10
BR112013008983A2 (pt) 2016-07-05
AU2016204638A1 (en) 2016-08-04
CN103458690A (zh) 2013-12-18
PL2637664T3 (pl) 2017-09-29
MX346730B (es) 2017-03-30
WO2012051559A2 (en) 2012-04-19
EP2637664A4 (de) 2014-09-10
AU2011315891A1 (en) 2013-05-23
EA201691759A1 (ru) 2017-05-31
KR20150002876A (ko) 2015-01-07
JP5806320B2 (ja) 2015-11-10
LT2637664T (lt) 2017-11-10
ZA201302746B (en) 2014-06-25
US9549926B2 (en) 2017-01-24
EP3106163A1 (de) 2016-12-21
US20140275098A1 (en) 2014-09-18
TW201219372A (en) 2012-05-16
AU2011315891B2 (en) 2015-08-13
HUE033346T2 (en) 2017-11-28
US20160346280A1 (en) 2016-12-01
CA2814518C (en) 2016-09-20
JP2015178528A (ja) 2015-10-08
KR20130069855A (ko) 2013-06-26
CA2814518A1 (en) 2012-04-19
JP2014506870A (ja) 2014-03-20
CN103458690B (zh) 2016-03-16
RS56135B1 (sr) 2017-10-31
NZ610012A (en) 2015-05-29
EA201390428A1 (ru) 2014-02-28
DK2637664T3 (en) 2017-06-19

Similar Documents

Publication Publication Date Title
ES2627944T3 (es) Composiciones y métodos de tratamiento de hipertensión pulmonar
ES2325207T3 (es) Combinacion que comprende valsartan, amlodipina e hidroclorotiazida.
ES2518418T3 (es) Composiciones de vasoconstricción y métodos de uso
ES2767084T3 (es) Nuevo uso
ES2604945T3 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento y prevención de pérdida de audición
ES2945866T3 (es) Pauta posológica de sacubitrilo-valsartán para el tratamiento de la insuficiencia cardíaca
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
US20090048173A1 (en) Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors
AU2009282104A1 (en) Treatment of pulmonary arterial hypertension
RU2409366C2 (ru) Фармацевтические композиции, включающие ингибиторы nep, ингибиторы системы, продуцирующей эндогенный эндотелин, и диуретики
ES2547145T3 (es) Regímenes de dosificación para el tratamiento de enfermedad vascular ocular
US20150125546A1 (en) Combination therapy for treating pulmonary hypertension
ES2247060T3 (es) Producto que comprende un inhibidor de la transduccion de las señales de las proteinas g heterotrimericas en asociacion con un agente antihipertensor para una utilizacion terapeutica en el tratamiento de la hipertension arterial.
ES2307896T3 (es) Uso de la 4-(2-fluorofenil)-6-metil-2-(1-piperazinil) tieno (2,3-d)-pirimidina para el tratamiento de la incontinencia urinaria.
ES2289305T3 (es) Medicamento para el tratamiento del "sindrome de la respuesta inflamatoria sistemica".
WO2007083985A1 (es) Composición farmacéutica sinergística de diclofenaco y clonixinato de lisina